Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial - PubMed
5 hours ago
- #tumor debulking
- #chemotherapy
- #metastatic colorectal cancer
- The ORCHESTRA trial investigated whether tumor debulking combined with chemotherapy improves survival in multiorgan metastatic colorectal cancer (mCRC).
- 382 patients were randomized to receive either chemotherapy alone or chemotherapy plus tumor debulking after initial response or stable disease.
- Median overall survival was 27.5 months in the chemotherapy group vs. 30.0 months in the debulking group, but the difference was not statistically significant (HR 0.88, P = .26).
- Progression-free survival was similar between groups (10.4 vs. 10.5 months, HR 0.83, P = .08).
- Serious adverse events were more frequent in the debulking group (53% vs. 39%, P = .006).
- The study concluded that tumor debulking did not significantly improve survival and should not be standard care for multiorgan mCRC.